Brege Laura
Director at MIRM; Director at ACAD; Director at PCRX, and 1 more
- Sold, on record
- $17.6M
- Dollars the filings state
- Form 4 sales
- 39
- Latest Sep 11, 2025
- Form 144 notices
- 3
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- MIRMMirum Pharmaceuticals, Inc.Director
- ACADACADIA PHARMACEUTICALS INCDirector
- PCRXPacira BioSciences, Inc.Director
- ONYX PHARMACEUTICALS INCEVP, Corporate Affairs
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ONYX PHARMACEUTICALS INC264,642 shares
- ACAD221,001 shares
- PCRX32,700 shares
- MIRM17,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 144 notice PCRXNoticeApr 3 2023
Filed to sell 7,000 shares ($285k)
Brege Laura, Director
10b5-1 planFirst sale on recordFiling
- 2 Form 4 sale PCRXRoutineApr 3 same day
Sold 7,000 shares at $40.72 ($285k)
Brege Laura, Director
10b5-1 planSold 40.8% of holdings ($698k position)10,147 shares leftFirst sale on recordFollows a Form 144Filing
- 3 Form 144 notice PCRXNoticeJun 5 +63 days
Filed to sell 600 shares ($23k)
Brege Laura, Director
10b5-1 planFiling
- 4 Form 4 sale PCRXRoutineJun 5 same day
Sold 600 shares at $38.74 ($23k)
Brege Laura, Director
10b5-1 planSold 5.9% of holdings ($393k position)9,547 shares leftFollows a Form 144Filing
- 5 Form 144 notice ACADNoticeJun 12 +7 days
Filed to sell 4,500 shares ($112k)
Brege Laura, Director
10b5-1 planFiling
- 6 Form 4 sale ACADRoutineJun 12 same day
Sold 4,500 shares at $24.87 ($112k)
Brege Laura, Director
10b5-1 planSold 25% of holdings ($448k position)13,502 shares leftFollows a Form 144Filing
- 7 Form 4 sale ACADUnusualJun 4 +723 days
Sold 14,446 shares at $21.78 ($315k)
Brege Laura, Director
No 10b5-1 planSold 48.9% of holdings ($643k position)15,095 shares leftFiling
- 8 Form 4 sale MIRMUnusualSep 11 +99 days
Sold 17,000 shares at $74.40 ($1.3M)
Brege Laura, Director
No 10b5-1 planSold 52% of holdings ($2.4M position)15,703 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (42)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | MIRM | Director | Form 4 sale | 17,000 | $1.3M | 52.0% | Unusual | SEC |
| Jun 4, 2025 | ACAD | Director | Form 4 sale | 14,446 | $315k | 48.9% | Unusual | SEC |
| Jun 12, 2023 | ACAD | Director | Form 4 sale | 4,500 | $112k | 25.0% | Routine | SEC |
| Jun 12, 2023 | ACAD | Director | Form 144 notice | 4,500 | $112k | Notice | SEC | |
| Jun 5, 2023 | PCRX | Director | Form 4 sale | 600 | $23k | 5.9% | Routine | SEC |
| Jun 5, 2023 | PCRX | Director | Form 144 notice | 600 | $23k | Notice | SEC | |
| Apr 3, 2023 | PCRX | Director | Form 4 sale | 7,000 | $285k | 40.8% | Routine | SEC |
| Apr 3, 2023 | PCRX | Director | Form 144 notice | 7,000 | $285k | Notice | SEC | |
| Jan 12, 2023 | ACAD | Director | Form 4 sale | 12,500 | $228k | 100.0% | Unusual | SEC |
| Nov 16, 2020 | PCRX | Director | Form 4 sale | 12,000 | $791k | 60.2% | Unusual | SEC |
| Jun 5, 2020 | PCRX | Director | Form 4 sale | 2,100 | $102k | 24.0% | Plan not stated | SEC |
| Jan 7, 2020 | ACAD | Director | Form 4 sale | 10,000 | $422k | 100.0% | Unusual | SEC |
| Jan 9, 2019 | ACAD | Director | Form 4 sale | 10,000 | $200k | 100.0% | Unusual | SEC |
| Jan 2, 2018 | ACAD | Director | Form 4 sale | 25,000 | $752k | 100.0% | Unusual | SEC |
| Jun 6, 2016 | PCRX | Director | Form 4 sale | 1,000 | $47k | 50.0% | Unusual | SEC |
| Feb 11, 2015 | ACAD | Director | Form 4 sale | 10,000 | $336k | 100.0% | Unusual | SEC |
| Sep 15, 2014 | ACAD | Director | Form 4 sale | 10,000 | $281k | 100.0% | Unusual | SEC |
| May 9, 2014 | PCRX | Director | Form 4 sale | 10,000 | $738k | 100.0% | Unusual | SEC |
| Apr 4, 2014 | ACAD | Director | Form 4 sale | 14,285 | $322k | 100.0% | Unusual | SEC |
| Jan 15, 2014 | ACAD | Director | Form 4 sale | 10,000 | $242k | 100.0% | Unusual | SEC |
| Dec 10, 2013 | ACAD | Director | Form 4 sale | 44,117 | $1M | 100.0% | Unusual | SEC |
| Oct 10, 2013 | ACAD | Director | Form 4 sale | 10,000 | $216k | 100.0% | Unusual | SEC |
| Sep 10, 2013 | ACAD | Director | Form 4 sale | 46,153 | $1.1M | 100.0% | Unusual | SEC |
| Oct 14, 2011 | ONYX PHARMACEUTICALS INC | EVP, Corporate Affairs | Form 4 sale | 10,000 | $360k | 20.1% | Plan not stated | SEC |
| Jul 14, 2011 | ONYX PHARMACEUTICALS INC | EVP, Corporate Affairs | Form 4 sale | 10,000 | $350k | 20.2% | Plan not stated | SEC |
| Apr 26, 2011 | ONYX PHARMACEUTICALS INC | EVP, Corporate Affairs | Form 4 sale | 10,000 | $350k | 20.2% | Plan not stated | SEC |
| Apr 1, 2011 | ONYX PHARMACEUTICALS INC | EVP, Corporate Affairs | Form 4 sale | 7,000 | $245k | 15.1% | Plan not stated | SEC |
| Jan 18, 2011 | ONYX PHARMACEUTICALS INC | EVP & Chief Operating Officer | Form 4 sale | 12,500 | $446k | 39.8% | Unusual | SEC |
| Nov 8, 2010 | ONYX PHARMACEUTICALS INC | EVP & Chief Operating Officer | Form 4 sale | 25,000 | $750k | 57.5% | Unusual | SEC |
| Apr 15, 2010 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $380k | 40.8% | Unusual | SEC |
| Apr 1, 2010 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 7,667 | $231k | 29.7% | Unusual | SEC |
| Jan 15, 2010 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $377k | 41.3% | Unusual | SEC |
| Dec 2, 2009 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $375k | 41.6% | Unusual | SEC |
| Jul 22, 2009 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 25,000 | $898k | 58.8% | Unusual | SEC |
| Apr 1, 2009 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 5,333 | $149k | 23.6% | Plan not stated | SEC |
| Jan 15, 2009 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $410k | 44.5% | Unusual | SEC |
| Nov 7, 2008 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $375k | 44.8% | Unusual | SEC |
| Jul 15, 2008 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $469k | 44.8% | Unusual | SEC |
| Apr 15, 2008 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $415k | 45.3% | Unusual | SEC |
| Apr 2, 2008 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 2,142 | $66k | 12.4% | Plan not stated | SEC |
| Jan 15, 2008 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 12,500 | $636k | 50.2% | Unusual | SEC |
| Aug 10, 2007 | ONYX PHARMACEUTICALS INC | EVP and Chief Business Officer | Form 4 sale | 50,000 | $1.6M | 81.3% | Unusual | SEC |